  Alzheimer disease (AD) is the leading cause of dementia, accounts for 60 to
80 percent cases. Two main factors called beta amyloid plaques and tangles are
prime suspects in damaging and killing nerve cells. However, oxidative stress,
the process which produces free radicals in cells, is believed to promote its
progression to the extent that it may responsible for the cognitive and
functional decline observed in AD. As of today there are few FDA approved drugs
in the market for treatment, but their cholinergic adverse effect, potentially
distressing toxicity and limited targets in AD pathology limits their use.
Therefore, it is crucial to find an effective compounds to combat AD. We choose
45 plant derived natural compounds that have antioxidant properties to slow
down disease progression by quenching free redicals or promoting endogenous
antioxidant capacity. However, we performed molecular docking studies to
investigate the binding interactions between natural compounds and 13 various
anti Alzheimer drug targets. Three known Cholinesterase inhibitors (Donepezil,
Galantamine and Rivastigmine) were taken as reference drugs over natural
compounds for comparison and drug likeness studies. Few of these compounds
showed good inhibitory activity besides anti oxidant activity. Most of these
compounds followed pharmacokinetics properties that make them potentially
promising drug candidates for the treatment of Alzheimer disease.
